Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
-
Published:2023-05
Issue:2
Volume:2
Page:100076
-
ISSN:2772-8293
-
Container-title:Journal of Allergy and Clinical Immunology: Global
-
language:en
-
Short-container-title:Journal of Allergy and Clinical Immunology: Global
Author:
Sehanobish Esha,
Ye Kenny,
Imam Kamran,
Sariahmed Karim,
Kurian Joshua,
Patel Jalpa,
Belletti Daniel,
Chung Yen,
Jariwala Sunit,
White Andrew,
Jerschow ElinaORCID
Reference22 articles.
1. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study;Bateman;Am J Respir Crit Care Med,2004
2. National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program;Wenzel;J Allergy Clin Immunol,2007
3. Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States;Song;J Asthma Allergy,2020
4. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma;Busse;J Allergy Clin Immunol,2001
5. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials;Castro;Lancet Respir Med,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献